{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:50:40Z","timestamp":1793386240303,"version":"4.5.0"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.metabol.2024.156083","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:45:30Z","timestamp":1732610730000},"page":"156083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The role of IL-1 family cytokines in diabetic cardiomyopathy"],"prefix":"10.1016","volume":"163","author":[{"given":"Qi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-yuan","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pi-jun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-zhe","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty Yuen-Kwan","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2024.156083_bb0005","first-page":"159","article-title":"DCRM 2.0: multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases","author":"Handelsman","year":"2024","journal-title":"Metabolism-Clinical and Experimental"},{"key":"10.1016\/j.metabol.2024.156083_bb0010","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2024.156083_bb0015","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.1974.03230510023016","article-title":"Diabetic cardiomyopathy","volume":"229","author":"Hamby","year":"1974","journal-title":"Jama"},{"key":"10.1016\/j.metabol.2024.156083_bb0020","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2337\/dbi23-0019","article-title":"Redefining diabetic cardiomyopathy: perturbations in substrate metabolism at the heart of its pathology","volume":"73","author":"Heather","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2024.156083_bb0025","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/07853890.2019.1602734","article-title":"Incidence and prognosis of heart failure in persons with type 2 diabetes compared with individuals without diabetes - a nation-wide study from Finland in 1996-2012","volume":"51","author":"Winell","year":"2019","journal-title":"Ann Med"},{"key":"10.1016\/j.metabol.2024.156083_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122087","article-title":"Current understanding of structural and molecular changes in diabetic cardiomyopathy","volume":"332","author":"Akhtar","year":"2023","journal-title":"Life Sci"},{"key":"10.1016\/j.metabol.2024.156083_bb0035","doi-asserted-by":"crossref","unstructured":"Congur I, Mingrone G, Guan K. Targeting endoplasmic reticulum stress as a potential therapeutic strategy for diabetic cardiomyopathy. Metab Clin Exp doi:https:\/\/doi.org\/10.1016\/j.metabol.2024.156062.","DOI":"10.1016\/j.metabol.2024.156062"},{"issue":"5","key":"10.1016\/j.metabol.2024.156083_bb0040","article-title":"Inflammation in diabetes complications: molecular mechanisms and therapeutic interventions","volume":"2024","author":"Zhao","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.metabol.2024.156083_bb0045","article-title":"Pathogenic pathways and therapeutic targets of inflammation in heart diseases: a focus on Interleukin-1","volume":"54","author":"Del Buono","year":"2024","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.metabol.2024.156083_bb0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-94-024-0921-5_2","article-title":"The interleukin-1 family","volume":"941","author":"Yazdi","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.metabol.2024.156083_bb0055","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41590-024-01777-1","article-title":"International nomenclature guidelines for the IL-1 family of cytokines and receptors","volume":"25","author":"Gaballa","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102617","article-title":"The IL-1 family cytokines and receptors in autoimmune diseases","volume":"19","author":"Migliorini","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.metabol.2024.156083_bb0065","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0070","first-page":"217","article-title":"Inflammasome signaling and regulation of interleukin-1 family cytokines","author":"Chan","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.metabol.2024.156083_bb0075","first-page":"22","article-title":"Mast cell cytokines IL-1, IL-33, and IL-36 mediate skin inflammation in psoriasis: a novel therapeutic approach with the anti-inflammatory cytokines IL-37, IL-38, and IL-1Ra","author":"Conti","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2024.156083_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108191","article-title":"The IL-18\/IL-18R1 signalling axis: diagnostic and therapeutic potential in hypertension and chronic kidney disease","volume":"239","author":"Thomas","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.metabol.2024.156083_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110747","article-title":"Impact of inflammation and anti-inflammatory modalities on diabetic cardiomyopathy healing: from fundamental research to therapy","volume":"123","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.metabol.2024.156083_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108053","article-title":"Targeting the NLRP3 inflammasome in cardiovascular diseases","volume":"236","author":"Toldo","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.metabol.2024.156083_bb0095","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jcmm.14741","article-title":"Interleukin-38 alleviates cardiac remodelling after myocardial infarction","volume":"24","author":"Wei","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.metabol.2024.156083_bb0100","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1073\/pnas.82.4.1204","article-title":"Identification of a membrane-associated interleukin 1 in macrophages","volume":"82","author":"Kurt-Jones","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.metabol.2024.156083_bb0105","doi-asserted-by":"crossref","first-page":"20684","DOI":"10.1073\/pnas.1116848108","article-title":"Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1\u03b1","volume":"108","author":"Berda-Haddad","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.metabol.2024.156083_bb0110","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.metabol.2024.156083_bb0115","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/imr.12615","article-title":"Function and regulation of IL-1\u03b1 in inflammatory diseases and cancer","volume":"281","author":"Malik","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.metabol.2024.156083_bb0120","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.redox.2013.03.001","article-title":"Redox-control of the alarmin, interleukin-1\u03b1","volume":"1","author":"McCarthy","year":"2013","journal-title":"Redox Biol"},{"key":"10.1016\/j.metabol.2024.156083_bb0125","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2337\/db13-1476","article-title":"Endogenous oils derived from human adipocytes are potent adjuvants that promote IL-1\u03b1-dependent inflammation","volume":"63","author":"Tynan","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2024.156083_bb0130","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ni.3503","article-title":"Interleukin 1\u03b1 and the inflammatory process","volume":"17","author":"Di Paolo","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0135","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0008-6363(00)00032-8","article-title":"Infarct scar: a dynamic tissue","volume":"46","author":"Sun","year":"2000","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2024.156083_bb0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/cmi.2016.34","article-title":"HMGB1, IL-1\u03b1, IL-33 and S100 proteins: dual-function alarmins","volume":"14","author":"Bertheloot","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0145","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijcard.2015.08.070","article-title":"Formation of the inflammasome during cardiac allograft rejection","volume":"201","author":"Shah","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.metabol.2024.156083_bb0150","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1113\/expphysiol.2012.069021","article-title":"The heart on fire: inflammasome and cardiomyopathy","volume":"98","author":"Abbate","year":"2013","journal-title":"Exp Physiol"},{"key":"10.1016\/j.metabol.2024.156083_bb0155","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S0735-1097(00)00526-X","article-title":"Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes","volume":"35","author":"Tatsumi","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2024.156083_bb0160","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/356768a0","article-title":"A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes","volume":"356","author":"Thornberry","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2024.156083_bb0165","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the Inflammasome as therapeutic targets in cardiovascular disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2024.156083_bb0170","first-page":"2481","article-title":"Spleen tyrosine kinase-induced JNK-dependent NLRP3 activation is involved in diabetic cardiomyopathy","volume":"43","author":"Li","year":"2019","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.metabol.2024.156083_bb0175","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1096\/fj.201902692R","article-title":"Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1\/miR-141-mediated NLRP3 inflammasome and TGF-\u03b21\/Smads signaling in diabetic cardiomyopathy","volume":"34","author":"Che","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.metabol.2024.156083_bb0180","doi-asserted-by":"crossref","first-page":"11043","DOI":"10.1038\/s41598-023-37678-w","article-title":"Artemisinin attenuates type 2 diabetic cardiomyopathy in rats through modulation of AGE-RAGE\/HMGB-1 signaling pathway","volume":"13","author":"Farrag","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2024.156083_bb0185","first-page":"23","article-title":"Allisartan isoproxil attenuates oxidative stress and inflammation through the SIRT1\/Nrf2\/NF-\u03baB signalling pathway in diabetic cardiomyopathy rats","author":"Jin","year":"2021","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.metabol.2024.156083_bb0190","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/biof.1587","article-title":"The role of interleukin 1 receptor antagonist in mesenchymal stem cell-based tissue repair and regeneration","volume":"46","author":"Harrell","year":"2020","journal-title":"Biofactors"},{"key":"10.1016\/j.metabol.2024.156083_bb0195","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0200","article-title":"Interleukin-1 receptor antagonist: a promising cytokine against human squamous cell carcinomas","volume":"9","author":"Ding","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.metabol.2024.156083_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122276","article-title":"Interleukin-1 receptor antagonist: an alternative therapy for cancer treatment","volume":"335","author":"Fang","year":"2023","journal-title":"Life Sci"},{"key":"10.1016\/j.metabol.2024.156083_bb0210","first-page":"14","article-title":"IL-1 receptor antagonist (IL-1Ra) levels and management of metabolic disorders","author":"Luotola","year":"2022","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.metabol.2024.156083_bb0215","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1056\/NEJMc071324","article-title":"Interleukin-1-receptor antagonist in type 2 diabetes mellitus","volume":"357","author":"Malozowski","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156083_bb0220","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1210\/en.2007-1059","article-title":"The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia","volume":"149","author":"Sauter","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2024.156083_bb0225","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S2213-8587(15)00034-0","article-title":"Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis","volume":"3","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2024.156083_bb0230","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1161\/ATVBAHA.117.309307","article-title":"Circulating levels of interleukin 1-receptor antagonist and risk of cardiovascular disease: meta-analysis of six population-based cohorts","volume":"37","author":"Herder","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2024.156083_bb0235","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with Canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156083_bb0240","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.acvd.2017.12.006","article-title":"Mechanism of interleukin-1 receptor antagonist protection against myocardial ischaemia\/reperfusion-induced injury","volume":"111","author":"Qian","year":"2018","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.metabol.2024.156083_bb0245","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.it.2016.03.007","article-title":"IL-33 in T cell differentiation, function, and immune homeostasis","volume":"37","author":"Peine","year":"2016","journal-title":"Trends Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0250","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cytogfr.2019.04.004","article-title":"The role of the IL-33\/ST2 axis in autoimmune disorders: friend or foe?","volume":"50","author":"Liu","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.metabol.2024.156083_bb0255","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.4049\/jimmunol.1003080","article-title":"The dual function cytokine IL-33 interacts with the transcription factor NF-\u03baB to dampen NF-\u03baB-stimulated gene transcription","volume":"187","author":"Ali","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0260","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/ni.3370","article-title":"Interleukin 33 is a guardian of barriers and a local alarmin","volume":"17","author":"Martin","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0265","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/cvr\/cvs015","article-title":"Reduction in IL-33 expression exaggerates ischaemia\/reperfusion-induced myocardial injury in mice with diabetes mellitus","volume":"94","author":"Rui","year":"2012","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2024.156083_bb0270","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12933-022-01616-3","article-title":"Prognostic value of soluble ST2, high-sensitivity cardiac troponin, and NT-proBNP in type 2 diabetes: a 15-year retrospective study","volume":"21","author":"Sabbatinelli","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2024.156083_bb0275","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/CIRCULATIONAHA.122.063014","article-title":"Interleukin-33 mediates cardiomyopathy after acute kidney injury by signaling to cardiomyocytes","volume":"147","author":"Florens","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2024.156083_bb0280","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/SHK.0b013e318160f215","article-title":"Interleukin 18 in the heart","volume":"30","author":"Wang","year":"2008","journal-title":"Shock"},{"key":"10.1016\/j.metabol.2024.156083_bb0285","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1600-065X.2008.00624.x","article-title":"IL-1, IL-18, and IL-33 families of cytokines","volume":"223","author":"Arend","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.metabol.2024.156083_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.919973","article-title":"Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment","volume":"13","author":"Ihim","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0295","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2119\/molmed.2014.00034","article-title":"Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure","volume":"20","author":"O\u2019Brien","year":"2014","journal-title":"Mol Med"},{"key":"10.1016\/j.metabol.2024.156083_bb0300","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2017.1","article-title":"Interleukin-18 mediates cardiac dysfunction induced by western diet independent of obesity and hyperglycemia in the mouse","volume":"7","author":"Carbone","year":"2017","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.metabol.2024.156083_bb0305","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.smim.2013.10.004","article-title":"Interleukin-37","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0310","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cyto.2015.04.009","article-title":"Interleukin 35 (IL-35) and IL-37: intestinal and peripheral expression by T and B regulatory cells in patients with inflammatory bowel disease","volume":"75","author":"Fonseca-Camarillo","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.metabol.2024.156083_bb0315","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cyto.2014.11.025","article-title":"IL-37: a new player in immune tolerance","volume":"72","author":"Chen","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.metabol.2024.156083_bb0320","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2174\/1389450121666200429114926","article-title":"IL-37 as a potential biotherapeutics of inflammatory diseases","volume":"21","author":"Bai","year":"2020","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.metabol.2024.156083_bb0325","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/all.15072","article-title":"IL-37 regulates allergic inflammation by counterbalancing pro-inflammatory IL-1 and IL-33","volume":"77","author":"Schr\u00f6der","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.metabol.2024.156083_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.696605","article-title":"Current understanding of IL-37 in human health and disease","volume":"12","author":"Su","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0335","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/imr.12605","article-title":"Suppression of inflammation and acquired immunity by IL-37","volume":"281","author":"Cavalli","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.metabol.2024.156083_bb0340","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fcell.2020.00056","article-title":"Interleukin 37 suppresses M1 macrophage polarization through inhibition of the Notch1 and nuclear factor kappa B pathways","volume":"8","author":"Zhou","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.metabol.2024.156083_bb0345","first-page":"15","article-title":"Protective effect of the polarity of macrophages regulated by IL-37 on atherosclerosis","author":"Huang","year":"2016","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.metabol.2024.156083_bb0350","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1684\/ecn.2011.0288","article-title":"IL-37: a new anti-inflammatory cytokine of the IL-1 family","volume":"22","author":"Boraschi","year":"2011","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.metabol.2024.156083_bb0355","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/5584_2020_488","article-title":"Interleukin-36: structure, signaling and function","volume":"21","author":"Zhou","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.metabol.2024.156083_bb0360","doi-asserted-by":"crossref","first-page":"861","DOI":"10.4049\/jimmunol.2100481","article-title":"The protective role of IL-36\/IL-36R signal in con A-induced acute hepatitis","volume":"208","author":"Wang","year":"2022","journal-title":"J Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0365","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.18632\/oncotarget.22814","article-title":"IL-36 cytokines in autoimmunity and inflammatory disease","volume":"9","author":"Ding","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.metabol.2024.156083_bb0370","first-page":"20","article-title":"IL-36 cytokines: regulators of inflammatory responses and their emerging role in immunology of reproduction","author":"Murrieta-Coxca","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2024.156083_bb0375","first-page":"11","article-title":"TGF-\u03b2 type 2 receptor-mediated modulation of the IL-36 family can be therapeutically targeted in osteoarthritis","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.metabol.2024.156083_bb0380","first-page":"131","article-title":"IL-36 in chronic inflammation and fibrosis - bridging the gap?","author":"Elias","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2024.156083_bb0385","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/imr.12612","article-title":"Biology of IL-38 and its role in disease","volume":"281","author":"van de Veerdonk","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.metabol.2024.156083_bb0390","doi-asserted-by":"crossref","DOI":"10.3390\/biom9080345","article-title":"IL-38: a new player in inflammatory autoimmune disorders","volume":"9","author":"Xie","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.metabol.2024.156083_bb0395","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.991","article-title":"The emerging role of IL-38 in diseases: a comprehensive review","volume":"11","author":"Chen","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.metabol.2024.156083_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155808","article-title":"Multifaceted roles of IL-38 in inflammation and cancer","volume":"151","author":"Diaz-Barreiro","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.metabol.2024.156083_bb0405","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00210-020-01920-3","article-title":"Interleukin-38 overexpression prevents bleomycin-induced mouse pulmonary fibrosis","volume":"394","author":"Xu","year":"2021","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"10.1016\/j.metabol.2024.156083_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107489","article-title":"The elevated expression of IL-38 serves as an anti-inflammatory factor in osteoarthritis and its protective effect in osteoarthritic chondrocytes","volume":"94","author":"Jiang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.metabol.2024.156083_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.03.082","article-title":"IL-38 ameliorates skin inflammation and limits IL-17 production from \u03b3\u03b4 T cells","volume":"27","author":"Han","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.metabol.2024.156083_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106264","article-title":"Interleukin-38 increases the insulin sensitivity in children with the type 2 diabetes","volume":"82","author":"Liu","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.metabol.2024.156083_bb0425","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000055916","article-title":"Cytokine production and antibodies against heat shock protein 60 in cardiomyopathies of different origins","volume":"68","author":"M\u00e1ndi","year":"2000","journal-title":"Pathobiology"},{"key":"10.1016\/j.metabol.2024.156083_bb0430","first-page":"193","article-title":"IL-18 serum levels in patients with obesity, prediabetes and newly diagnosed type 2 diabetes","volume":"19","author":"Nedeva","year":"2022","journal-title":"Iran J Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0435","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.it.2023.06.002","article-title":"Physiological role of cytokines in the regulation of mammalian metabolism","volume":"44","author":"de Baat","year":"2023","journal-title":"Trends Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033438","article-title":"Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure","volume":"7","author":"Van Tassell","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2024.156083_bb0445","first-page":"10","article-title":"Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (recently decompensated heart failure Anakinra response trial)","author":"Van Tassell","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.metabol.2024.156083_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002901","article-title":"Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): a multicentre, open-label, randomised controlled trial","volume":"16","author":"Ruscitti","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.metabol.2024.156083_bb0455","doi-asserted-by":"crossref","DOI":"10.1097\/MAT.0000000000001347","article-title":"Interleukin-1 receptor antagonism as adjunct therapy for heart failure patients with left ventricular assist devices","volume":"67","author":"Healy","year":"2021","journal-title":"ASAIO J"},{"key":"10.1016\/j.metabol.2024.156083_bb0460","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.clinthera.2014.08.004","article-title":"Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus","volume":"36","author":"Noe","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.metabol.2024.156083_bb0465","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.diabet.2013.07.003","article-title":"Impact of interleukin-1\u03b2 antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial","volume":"39","author":"Hensen","year":"2013","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2024.156083_bb0470","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2016.07.768","article-title":"Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance","volume":"68","author":"Choudhury","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2024.156083_bb0475","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","article-title":"Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy","volume":"43","author":"Ridker","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2024.156083_bb0480","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2020.08.011","article-title":"Inhibition of interleukin-1\u03b2 and reduction in atherothrombotic cardiovascular events in the CANTOS trial","volume":"76","author":"Everett","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2024.156083_bb0485","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156083_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101649","article-title":"Canakinumab in patients with COVID-19 and type 2 diabetes - a multicentre, randomised, double-blind, placebo-controlled trial","volume":"53","author":"Hepprich","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.metabol.2024.156083_bb0495","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/COH.0000000000000756","article-title":"Cardiovascular disease risk in women living with HIV","volume":"17","author":"Kentoffio","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.metabol.2024.156083_bb0500","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.2337\/dc11-2219","article-title":"Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes","volume":"35","author":"Cavelti-Weder","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.156083_bb0505","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12967-021-02828-z","article-title":"Interleukin-1 blockade with RPH-104 in patients with acute ST-elevation myocardial infarction: study design and rationale","volume":"19","author":"Samsonov","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.metabol.2024.156083_bb0510","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/CIRCULATIONAHA.124.069396","article-title":"Results of international, double-blind, randomized, placebo-controlled, phase IIa study of interleukin-1 blockade with RPH-104 (Goflikicept) in patients with ST-segment-elevation myocardial infarction (STEMI)","volume":"150","author":"Abbate","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2024.156083_bb0515","first-page":"141","article-title":"Recurrent pericarditis and interleukin (IL)-1 inhibitors","author":"Principi","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.metabol.2024.156083_bb0520","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc09-0533","article-title":"Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes","volume":"32","author":"Larsen","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.156083_bb0525","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156083_bb0530","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis","volume":"117","author":"Ikonomidis","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2024.156083_bb0535","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1007\/s00210-024-03152-1","article-title":"Interleukin 1\u03b2 receptor blocker (Anakinra) and regenerative stem cell therapy: two novel approaches effectively ameliorating diabetic cardiomyopathy","volume":"397","author":"Mahmoud","year":"2024","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"10.1016\/j.metabol.2024.156083_bb0540","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156083_bb0545","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2024.156083_bb0550","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with Canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2024.156083_bb0555","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.jacc.2018.03.002","article-title":"Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes","volume":"71","author":"Everett","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2024.156083_bb0560","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/oby.20004","article-title":"XOMA 052, an anti-IL-1\u03b2 monoclonal antibody, prevents IL-1\u03b2-mediated insulin resistance in 3T3-L1 adipocytes","volume":"21","author":"Handa","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2024.156083_bb0565","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1517\/13543784.2014.947026","article-title":"Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?","volume":"23","author":"Pafili","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.metabol.2024.156083_bb0570","first-page":"755","article-title":"Gevokizumab, an anti-IL-1\u03b2 mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease","volume":"12","author":"Geiler","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.metabol.2024.156083_bb0575","unstructured":"Study of the effects of XOMA 052 on insulin production in subjects with well controlled type 1 diabetes. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00998699?term=gevokizumab."},{"key":"10.1016\/j.metabol.2024.156083_bb0580","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/1574884715666200716145935","article-title":"Inhibition of Interleukin-1 in the treatment of selected cardiovascular complications","volume":"16","author":"Heydari","year":"2021","journal-title":"Curr Rev Clin Exp Pharmacol"},{"key":"10.1016\/j.metabol.2024.156083_bb0585","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jacbts.2017.06.005","article-title":"The IL-1\u03b2 antibody gevokizumab limits cardiac remodeling and coronary dysfunction in rats with heart failure","volume":"2","author":"Harouki","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.metabol.2024.156083_bb0590","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jacc.2023.04.046","article-title":"Treatment of idiopathic recurrent pericarditis with goflikicept: phase II\/III study results","volume":"82","author":"Myachikova","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2024.156083_bb0595","first-page":"10","article-title":"Affinity capture elution (ACE) ELISA method development and validation for novel RPH-104 drug immunogenicity evaluation","author":"Kolganova","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.metabol.2024.156083_bb0600","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/heartjnl-2020-317928","article-title":"Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial","volume":"107","author":"Klein","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.metabol.2024.156083_bb0605","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.metabol.2024.156083_bb0610","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156083_bb0615","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.metabol.2024.156083_bb0620","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/pedi.12634","article-title":"A phase I study of anti-inflammatory therapy with rilonacept in adolescents and adults with type 1 diabetes mellitus","volume":"19","author":"White","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.metabol.2024.156083_bb0625","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keae440","article-title":"Long-term efficacy of MAS825, a bispecific anti-IL1\u03b2 and IL-18 monoclonal antibody, in two patients with sJIA and recurrent episodes of MAS","author":"Caorsi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.metabol.2024.156083_bb0630","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300155","article-title":"Brepocitinib, zimlovisertib, and ropsacitinib in hidradenitis suppurativa","volume":"3","author":"Kimball","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.metabol.2024.156083_bb0635","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s40265-022-01801-4","article-title":"Spesolimab: first approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.metabol.2024.156083_bb0640","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2024.01.034","article-title":"The expanding horizon of anti-IL-36 therapy","volume":"90","author":"Heymann","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.metabol.2024.156083_bb0645","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.ekir.2024.03.009","article-title":"Inhibition of Interleukin-33 to reduce glomerular endothelial inflammation in diabetic kidney disease","volume":"9","author":"Hofherr","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.metabol.2024.156083_bb0650","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1038\/s41598-023-36642-y","article-title":"Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE\/EGFR to reduce inflammation and epithelial dysfunction","volume":"13","author":"England","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2024.156083_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107670","article-title":"A randomized clinical trial of bermekimab treatment for clinical improvement of systemic sclerosis","volume":"26","author":"Solomonidi","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.metabol.2024.156083_bb0660","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-024-02294-z","article-title":"Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure","volume":"23","author":"Wang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2024.156083_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.109252","article-title":"GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1\u03b2-induced metabolic disturbance and mitochondrial dysfunction","volume":"332","author":"Zhang","year":"2020","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.metabol.2024.156083_bb0670","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10557-013-6498-1","article-title":"Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model","volume":"28","author":"Luo","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.metabol.2024.156083_bb0675","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1042\/CS20130043","article-title":"NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin","volume":"126","author":"Satoh","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.metabol.2024.156083_bb0680","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12016-020-08791-9","article-title":"Anti-inflammatory action of statins in cardiovascular disease: the role of Inflammasome and toll-like receptor pathways","volume":"60","author":"Koushki","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.metabol.2024.156083_bb0685","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2020.08.011","article-title":"Inhibition of interleukin-1beta and reduction in atherothrombotic cardiovascular events in the CANTOS trial","volume":"76","author":"Everett","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2024.156083_bb0690","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.18808","article-title":"Concordance with screening and treatment guidelines for chronic kidney disease in type 2 diabetes","volume":"7","author":"Edmonston","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524003111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524003111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T05:48:00Z","timestamp":1738993680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524003111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":138,"alternative-id":["S0026049524003111"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156083","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of IL-1 family cytokines in diabetic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156083"}}